A Randomized, Blind,Single dose, Parallel control Phase I Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Full human recombinant monoclonal antibody against RANKL for injection and Prolia in Healthy Volunteers
Latest Information Update: 10 Aug 2018
At a glance
- Drugs KN-012 (Primary) ; Denosumab
- Indications Osteoporosis
- Focus Pharmacokinetics
Most Recent Events
- 10 Aug 2018 New trial record